Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch

Blood (2023) 142 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2023-181871

Published: 2023

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina

Blood (2022) 140 (Supplement 1): 9087–9088.

https://doi.org/10.1182/blood-2022-159471

Published: 2022

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140664

Published: 2020

Journal Articles

In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?

Gabriele Greve, Geoffroy Andrieux, Pascal Schlosser, Nadja Blagitko-Dorfs, Hans-Walter Lindemann, MD, Michael Heuser, MD, Andreas Neubauer, Jürgen Krauter, MD, Helmut R. Salih, MD, Gerhard Heil, Carsten Schwänen, Carsten Müller-Tidow, Arnold Ganser, MD, Hartmut Döhner, MD, Dietmar Pfeifer, Björn Hackanson, Olga Grishina, Melanie Boerries, Michael Lübbert

Blood (2018) 132 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2018-99-118762

Published: 2018

Journal Articles

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Jürgen Finke, MD, Claudia Schmoor, Matthias Stelljes, MD, Andreas Burchert, MD, Peter Dreger, Eva-Maria Wagner, MD, Martin Bornhäuser, Kristina Sohlbach, MD, Natalie Schub, MD, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, MD, Olga Grishina

Blood (2018) 132 (Supplement 1): 210.

https://doi.org/10.1182/blood-2018-99-118999

Published: 2018

Journal Articles

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Blood (2018) 132 (Supplement 1): 720.

https://doi.org/10.1182/blood-2018-99-115974

Published: 2018

Journal Articles

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Blood (2016) 128 (22): 589.

https://doi.org/10.1182/blood.V128.22.589.589

Published: 2016

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

Jürgen Finke, MD, Claudia Schmoor, PhD, Wolfgang A Bethge, MD, Hellmut Ottinger, Priv.-Doz. Dr. MD, Matthias Stelljes, Liisa Volin, MD PhD, Dominik Heim, MD, Hartmut Bertz, MD, Olga Grishina, MD, Gerard Socie

Blood (2015) 126 (23): 853.

https://doi.org/10.1182/blood.V126.23.853.853

Published: 2015

Journal Articles

In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response

Blood (2014) 124 (21): 870.

https://doi.org/10.1182/blood.V124.21.870.870

Published: 2014

Journal Articles

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Juergen Finke, Claudia Schmoor, PhD, Wolfgang A. Bethge, MD, Hellmut Ottinger, MD, Matthias Stelljes, MD, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, Hartmut Bertz, Olga Grishina, MD, Gerard Socie

Blood (2012) 120 (21): 3090.

https://doi.org/10.1182/blood.V120.21.3090.3090

Published: 2012

Journal Articles

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Blood (2011) 117 (23): 6375–6382.

https://doi.org/10.1182/blood-2011-01-329821

Published: 2011

Includes: Supplemental data

Journal Articles

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Gérard Socié, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Jurgen Finke, MD

Blood (2010) 116 (21): 212.

https://doi.org/10.1182/blood.V116.21.212.212

Published: 2010

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Jurgen Finke, MD, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Gérard Socié

Blood (2010) 116 (21): 1249.

https://doi.org/10.1182/blood.V116.21.1249.1249

Published: 2010

NARROW

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only